Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys

Alvin V Terry, Jerry J. Buccafusco, Gerd D. Bartoszyk

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Rationale: The superior cognitive effects of atypical neuroleptics over typical agents reported in the schizophrenia literature are often attributed to the more prominent antagonist activity of the atypical drugs at serotonin 5HT2A receptors. However, atypical neuroleptics also have activity at many additional neurotransmitter receptors and few studies have specifically (and prospectively) tested the hypothesis that 5HT2A antagonism alone results in enhanced cognitive function. Objectives: The purpose of this study was to evaluate the selective 5-HT2A antagonist, 7-{4-[2-(4-fluoro- phenyl)-ethyl]-piperazine-1-carbonyl}-1H-indole-3-carbonitrile HCl (EMD 281014) in young and aged monkeys in a test designed to assess working memory function. Methods: Four oral doses (0.1, 1.0, 3.0, and 10.0 mg/kg) of EMD 281014 were evaluated in six young adult (mean age=9.2 years) and eight aged rhesus macaques (mean age=24.9 years) trained to perform a computer-assisted delayed matching-to-sample (DMTS) task. Results: Depending on dose, EMD 281014 improved DMTS accuracy in young and aged monkeys primarily at either the medium or long retention intervals. While the latencies associated with incorrect color selections (choices latencies) tended to be longer than those associated with correct selections (particularly in the aged subjects) under baseline conditions, there were no significant effects of EMD 281014 on either sample or choice latencies in either age group. In addition, no adverse effects were observed across the range of doses evaluated in either cohort of animals. Conclusion: These experiments, conducted in a non-human primate model, suggest that selective 5HT2A antagonists such as EMD 281014 could offer therapeutic benefit to younger and older psychiatric patients by improving working memory function.

Original languageEnglish (US)
Pages (from-to)725-732
Number of pages8
JournalPsychopharmacology
Volume179
Issue number4
DOIs
StatePublished - Jun 1 2005

Fingerprint

Serotonin 5-HT2 Receptor Antagonists
Macaca mulatta
Short-Term Memory
Antipsychotic Agents
Haplorhini
Neurotransmitter Receptor
Serotonin Receptors
Cognition
Primates
Psychiatry
EMD 281014
Young Adult
Schizophrenia
Age Groups
Color
Pharmaceutical Preparations

Keywords

  • 5-HT
  • Alzheimer's disease
  • Cognition
  • Learning
  • Memory
  • Non-human primate
  • Receptors
  • Schizophrenia
  • Serotonin
  • Working memory

ASJC Scopus subject areas

  • Pharmacology

Cite this

Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. / Terry, Alvin V; Buccafusco, Jerry J.; Bartoszyk, Gerd D.

In: Psychopharmacology, Vol. 179, No. 4, 01.06.2005, p. 725-732.

Research output: Contribution to journalArticle

@article{616147a50abb40fb96ddc1edefa9c69f,
title = "Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys",
abstract = "Rationale: The superior cognitive effects of atypical neuroleptics over typical agents reported in the schizophrenia literature are often attributed to the more prominent antagonist activity of the atypical drugs at serotonin 5HT2A receptors. However, atypical neuroleptics also have activity at many additional neurotransmitter receptors and few studies have specifically (and prospectively) tested the hypothesis that 5HT2A antagonism alone results in enhanced cognitive function. Objectives: The purpose of this study was to evaluate the selective 5-HT2A antagonist, 7-{4-[2-(4-fluoro- phenyl)-ethyl]-piperazine-1-carbonyl}-1H-indole-3-carbonitrile HCl (EMD 281014) in young and aged monkeys in a test designed to assess working memory function. Methods: Four oral doses (0.1, 1.0, 3.0, and 10.0 mg/kg) of EMD 281014 were evaluated in six young adult (mean age=9.2 years) and eight aged rhesus macaques (mean age=24.9 years) trained to perform a computer-assisted delayed matching-to-sample (DMTS) task. Results: Depending on dose, EMD 281014 improved DMTS accuracy in young and aged monkeys primarily at either the medium or long retention intervals. While the latencies associated with incorrect color selections (choices latencies) tended to be longer than those associated with correct selections (particularly in the aged subjects) under baseline conditions, there were no significant effects of EMD 281014 on either sample or choice latencies in either age group. In addition, no adverse effects were observed across the range of doses evaluated in either cohort of animals. Conclusion: These experiments, conducted in a non-human primate model, suggest that selective 5HT2A antagonists such as EMD 281014 could offer therapeutic benefit to younger and older psychiatric patients by improving working memory function.",
keywords = "5-HT, Alzheimer's disease, Cognition, Learning, Memory, Non-human primate, Receptors, Schizophrenia, Serotonin, Working memory",
author = "Terry, {Alvin V} and Buccafusco, {Jerry J.} and Bartoszyk, {Gerd D.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1007/s00213-004-2114-1",
language = "English (US)",
volume = "179",
pages = "725--732",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys

AU - Terry, Alvin V

AU - Buccafusco, Jerry J.

AU - Bartoszyk, Gerd D.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Rationale: The superior cognitive effects of atypical neuroleptics over typical agents reported in the schizophrenia literature are often attributed to the more prominent antagonist activity of the atypical drugs at serotonin 5HT2A receptors. However, atypical neuroleptics also have activity at many additional neurotransmitter receptors and few studies have specifically (and prospectively) tested the hypothesis that 5HT2A antagonism alone results in enhanced cognitive function. Objectives: The purpose of this study was to evaluate the selective 5-HT2A antagonist, 7-{4-[2-(4-fluoro- phenyl)-ethyl]-piperazine-1-carbonyl}-1H-indole-3-carbonitrile HCl (EMD 281014) in young and aged monkeys in a test designed to assess working memory function. Methods: Four oral doses (0.1, 1.0, 3.0, and 10.0 mg/kg) of EMD 281014 were evaluated in six young adult (mean age=9.2 years) and eight aged rhesus macaques (mean age=24.9 years) trained to perform a computer-assisted delayed matching-to-sample (DMTS) task. Results: Depending on dose, EMD 281014 improved DMTS accuracy in young and aged monkeys primarily at either the medium or long retention intervals. While the latencies associated with incorrect color selections (choices latencies) tended to be longer than those associated with correct selections (particularly in the aged subjects) under baseline conditions, there were no significant effects of EMD 281014 on either sample or choice latencies in either age group. In addition, no adverse effects were observed across the range of doses evaluated in either cohort of animals. Conclusion: These experiments, conducted in a non-human primate model, suggest that selective 5HT2A antagonists such as EMD 281014 could offer therapeutic benefit to younger and older psychiatric patients by improving working memory function.

AB - Rationale: The superior cognitive effects of atypical neuroleptics over typical agents reported in the schizophrenia literature are often attributed to the more prominent antagonist activity of the atypical drugs at serotonin 5HT2A receptors. However, atypical neuroleptics also have activity at many additional neurotransmitter receptors and few studies have specifically (and prospectively) tested the hypothesis that 5HT2A antagonism alone results in enhanced cognitive function. Objectives: The purpose of this study was to evaluate the selective 5-HT2A antagonist, 7-{4-[2-(4-fluoro- phenyl)-ethyl]-piperazine-1-carbonyl}-1H-indole-3-carbonitrile HCl (EMD 281014) in young and aged monkeys in a test designed to assess working memory function. Methods: Four oral doses (0.1, 1.0, 3.0, and 10.0 mg/kg) of EMD 281014 were evaluated in six young adult (mean age=9.2 years) and eight aged rhesus macaques (mean age=24.9 years) trained to perform a computer-assisted delayed matching-to-sample (DMTS) task. Results: Depending on dose, EMD 281014 improved DMTS accuracy in young and aged monkeys primarily at either the medium or long retention intervals. While the latencies associated with incorrect color selections (choices latencies) tended to be longer than those associated with correct selections (particularly in the aged subjects) under baseline conditions, there were no significant effects of EMD 281014 on either sample or choice latencies in either age group. In addition, no adverse effects were observed across the range of doses evaluated in either cohort of animals. Conclusion: These experiments, conducted in a non-human primate model, suggest that selective 5HT2A antagonists such as EMD 281014 could offer therapeutic benefit to younger and older psychiatric patients by improving working memory function.

KW - 5-HT

KW - Alzheimer's disease

KW - Cognition

KW - Learning

KW - Memory

KW - Non-human primate

KW - Receptors

KW - Schizophrenia

KW - Serotonin

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=20044394414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044394414&partnerID=8YFLogxK

U2 - 10.1007/s00213-004-2114-1

DO - 10.1007/s00213-004-2114-1

M3 - Article

C2 - 15619109

AN - SCOPUS:20044394414

VL - 179

SP - 725

EP - 732

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -